Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients

Elsayed, 2020, Association of interleukin-17 with peripheral spondyloarthropathic changes detected by musculoskeletal ultrasound in psoriatic patients, Egypt Rheumatol, 42, 303, 10.1016/j.ejr.2019.04.011 El Hadidi, 2008, Involvement of IL-23 in psoriasis and psoriatic arthritispatients; possible role in pathogenesis, J Egypt Wom Dermatol Soc, 5, 70 Kaeley, 2020, Enthesitis in psoriatic arthritis (Part 2): imaging, Rheumatology, 59, 15, 10.1093/rheumatology/keaa040 Kaeley, 2018, Enthesitis: a hallmark of psoriatic arthritis, Semin Arthritis Rheum, 48, 35, 10.1016/j.semarthrit.2017.12.008 Emad, 2012, Knee Enthesitis Working Group. Knee enthesitis and synovitis on magnetic resonance imaging in patients with psoriasis without arthritic symptoms, J Rheumatol, 39, 1979, 10.3899/jrheum.120301 ElMallah, 2019, The incremental value of ultrasound in detection of subclinical peripheral enthesitis in patients with spondyloarthritis, Egypt Rheumatol, 42, 255, 10.1016/j.ejr.2019.04.005 Maatallah, 2020, Plantar fascia enthesitis: Clinical, radiographic and ultrasound findings in patients with axial spondyloarthritis, Egypt Rheumatol, 42, 267, 10.1016/j.ejr.2020.07.011 Madland, 2007, S100 proteinscalprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritiswith lowdisease activity, J Rheumatol, 34, 2089 Nordal, 2014, Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome, Scand J Rheumatol, 43, 76, 10.3109/03009742.2013.848930 Ometto, 2017, Calprotectin in rheumatic diseases, Exp Biol Med, 242, 859, 10.1177/1535370216681551 Vogl, 2007, Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock, Nat Med, 13, 1042, 10.1038/nm1638 Frosch, 2009, The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 883, 10.1002/art.24349 Grossi, 2017, A proposed serum calprotectin IgG cut-off level for diagnosing inflammatory arthritis, Curr Rheumatol Rev, 13, 93, 10.2174/1573397112666160629085231 Healy, 2008, Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis, Arthritis Rheum, 59, 686, 10.1002/art.23568 Hartung, 2018, Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice, Open Access Rheumatol, 10, 161, 10.2147/OARRR.S179472 Kristensen, 2016, Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound, Muscles Ligaments Tendons J, 6, 241, 10.32098/mltj.02.2016.12 Chiricozzi, 2020, Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study, J Dermatolog Treat, 31, 476, 10.1080/09546634.2019.1671577 Nast, 2018, Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials, Br J Dermatol, 178, 400, 10.1111/bjd.15864 Wervers, 2019, Association of physical activity and medication with enthesitis on ultrasound in psoriatic arthritis, J Rheumatol, 46, 1290, 10.3899/jrheum.180782 García-Arias, 2013, Calprotectin in rheumatoid arthritis, Mol Diagn Ther, 17, 49, 10.1007/s40291-013-0016-9 Choi, 2015, MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann Rheum Dis, 74, 499, 10.1136/annrheumdis-2013-203923 Radwan, 2021, The relationship of serum calprotectin with disease activity, functional status, ultrasonographic findings and radiological damage in rheumatoid arthritis patients, Egypt Rheumatol, 43, 147, 10.1016/j.ejr.2021.01.003 Guo, 2016, Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease, Clin Rheumatol, 35, 73, 10.1007/s10067-015-3108-6 Oktayoglu, 2014, Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life, J Invest Med, 62, 880, 10.1097/JIM.0000000000000095 Inciarte-Mundo, 2016, Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity, Arthritis Res Ther, 18, 160, 10.1186/s13075-016-1032-z Haga, 1993, Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity, Lupus, 2, 47, 10.1177/096120339300200108 Krzesiek, 2015, Fecal calprotectin as an activity marker of inflammatory bowel disease in children, Adv Clin Exp Med, 24, 815, 10.17219/acem/26003 Roth, 2003, Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules, Trends Immunol, 24, 155, 10.1016/S1471-4906(03)00062-0 Sokolova, 2020, A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations, Arthritis Res Ther, 22, 26, 10.1186/s13075-020-2111-8 Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther 2020; 22:1-1 Hamza, 2019, Serum calprotectin as a predictive biomarker in the treatment of psoriasis vulgaris with methotrexate, J Egypt Wom Dermatol Soc, 16, 112, 10.4103/JEWD.JEWD_12_19 Qian, 2018, Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors, Eur Rev Med Pharmacol Sci, 22, 4299 Aochi, 2011, Markedly elevated serum levels of calciumbinding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages, J Am Acad Dermatol, 64, 879, 10.1016/j.jaad.2010.02.049 Mease, 2016, The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis, Arthritis Rheumatol, 68, 2163, 10.1002/art.39700 Erfan, 2015, Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris, Dermatol Sin, 33, 1, 10.1016/j.dsi.2014.08.003 Hansson, 2014, S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis, J Immunol Res, 20141 Hurnakova, 2017, Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study, PLoS ONE, 12, 10.1371/journal.pone.0183420 Ramírez, 2016, Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission, Arthritis Res Ther, 18, 74, 10.1186/s13075-016-0970-9 Wervers, 2018, Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers, Scand J Rheumatol, 47, 291, 10.1080/03009742.2017.1393695